Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue and operating profit increased in the clinical testing and ICT businesses. In the clinical testing business, the increase in contracted tests through sales activities focused on major metropolitan areas, appropriate sales price adjustments, a review of the collection system and more efficient testing operations contributed to results. In the ICT business, stepped-up sales activities, increases in the number of contracts and implementations, and the launch of sales of new services contributed to results.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥22,148 million (YoY +2.4%) |
| Operating profit | ¥1,490 million (YoY +38.2%) |
| Ordinary income | ¥1,586 million (YoY +34.3%) |
| Profit attributable to owners of the parent | ¥957 million (YoY +19.2%) |
| Net income per share | ¥96.10 |
| Equity ratio | End of the current fiscal period 69.5 / End of previous period 70 |
| Total assets | ¥37,044 million |
| Net assets | ¥25,791 million |
| Full-year earnings forecast | Net Sales ¥44,300 million (YoY +1.7%) / Operating profit ¥2,700 million (YoY +8.1%) / Ordinary income ¥2,850 million (YoY +6.0%) / Net income ¥2,020 million (YoY +0.2%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥125 → ¥128（+2.4%） |
| Segment revenue | Clinical Testing Business ¥13,839 million (YoY +3.2%), Dispensing Pharmacy Business ¥7,391 million (YoY -1.9%), ICT business ¥917 million (YoY +34.6%) |
| Segment profit | Clinical Testing Business ¥1,182 million (YoY +26.2%), Dispensing Pharmacy Business ¥239 million (YoY -1.0%), ICT business ¥242 million (YoY +45.4%) |
| Impairment loss | ¥0 million (the assets subject to impairment were not specified) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets ¥0 million / Extraordinary loss Loss on disposal of fixed assets ¥1 million, Impairment loss ¥0 million |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No ( 대상者: Not disclosed) |
| Issued Shares at Period-End | 10,680,177 |
| Treasury Shares at Period-End | 806,609 |
| Factors Behind Changes in Business Performance | Revenue and operating profit increased in the clinical testing and ICT businesses. In the clinical testing business, the increase in contracted tests through sales activities focused on major metropolitan areas, appropriate sales price adjustments, a review of the collection system and more efficient testing operations contributed to results. In the ICT business, stepped-up sales activities, increases in the number of contracts and implementations, and the launch of sales of new services contributed to results. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because revenue and operating profit increased in the clinical testing and ICT businesses. In the clinical testing business, the number of contracted tests increased as a result of stepped-up sales activities, while in the ICT business, the number of contracts and implementations increased as a result of stepped-up sales activities.